Such differences are likely to contribute to the variability in the expression of downstream factors associated with the IFN-γ/STAT1 pathway, which may lead to divergent effects—either promoting or inhibiting different gastrointestinal tumor progression. The gene discussed is IFNG; the disease is digestive system neoplasm.